Auris Medical (EARS) Stock: This Run Could Go Far Higher

0

Auris Medical Holding AG EARS Stock NewsAuris Medical Holding AG (NASDAQ: EARS) is flying early on in the trading session this morning, but the company hasn’t released any news. There haven’t been any SEC filings either. So, what’s the deal? Well, it looks like the stock is gearing up for a short squeeze and savvy traders are working to get in ahead of this thing. Today, we’ll talk about:

  • Why I believe that EARS is headed for a short squeeze;
  • what we’re seeing from the stock; and
  • what we’ll be watching for ahead.

EARS Is Lining Up For A Short Squeeze

As mentioned above, Auris Medical is having a strong start to the trading session this morning, even though it is lacking any meaningful news. At the end of the day, this looks like a short squeeze in the making and excited traders getting in ahead of the gains. Here’s why I say that:

EARS is a stock that has tremendously high short interest. According to ShortSqueeze.com, more than 70% of the float is traded short. To add to the evidence here, much of that short interest came from a recent, yet overwhelming increase of 176% in short activity. When short interest is this high, the wind blowing in the right direction can lead to a short squeeze.




Going further, there’s quite a bit for investors to be excited about when it comes to EARS. Just a couple of weeks ago, the company announced positive results from a second Phase 1 clinical trial that evaluated intranasal betahistine in healthy volunteers. The study met its primary endpoint, showing superior bioavailability over a range of four intranasal betahistine doses when compared to oral betahistine. Furthermore, the safety and tolerability profiles were strong. So, this vertigo treatment is showing some serious promise and with the end of Phase 1 behind us, it’s only a matter of time before we see a clinical or regulatory catalyst as the company furthers its intranasal betahistine assess through the development process. All in all, it’s not a good time to be short.

What We’re Seeing From The Stock 

Short interest is an interesting factor, and it’s one that tends to lead to some of the biggest gains that we see in the market. At the end of the day, I believe that Auris Medical is on its way to a short squeeze that will be one of these monumental runs. That may be starting today as the stock is lighting up enough for our partners at Trade Ideas to send the alert. Currently (10:32), EARS is trading at $0.71 per share after a gain of $0.073 per share or 11.46% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on EARS. In particular, we’re interested in following the continued development of intranasal betahistine as the treatment seems to be showing promise. We’re also interested in following the potential for a short squeeze here as we believe that it is everpresent. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Previous articleNXP Semiconductors (NXPI) Stock: Up On Qualcomm Breakup Fee
Next articleNio (NIO) Stock: Here’s What’s Going On
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at CNAFinanceHelp@gmail.com Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.

LEAVE A REPLY

Please enter your comment!
Please enter your name here